All the news Showing 6 of 46 articles from: Nucleotide Ns5B polymerase inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir demonstrates high response rate in interferon-free combination with ribavirin and GS-5885 Liz Highleyman / 15 November 2012 The hepatitis C polymerase inhibitor sofosbuvir produced high rates of sustained virological response in genotype 1 patients when combined with ribavirin and the HCV NS5A inhibitor GS-5885, according to data presented this week ... New hepatitis C drugs danoprevir and mericitabine are safe and effective for prior non-responders and people with cirrhosis Liz Highleyman / 12 November 2012 The experimental hepatitis C drugs danoprevir and mericitabine, with or without pegylated interferon and ribavirin, showed good safety and efficacy in previously treated patients, according to findings from the MATTERHORN study presented at ... Sofosbuvir appears safe and effective for HIV/HCV co-infected people Liz Highleyman / 13 September 2012 HIV/HCV co-infected people taking the experimental hepatitis C virus polymerase inhibitor sofosbuvir (formerly GS-7977) experienced a rapid decline in HCV viral load similar to that seen in HIV-negative patients, researchers reported on Wednesday ... GS-7977 with interferon/ribavirin cures most treatment-naive hepatitis C patients in 12 weeks Liz Highleyman / 30 April 2012 Adding GS-7977 to pegylated interferon and ribavirin for 12 weeks led to a sustained response rate of 90% for previously untreated chronic hepatitis C patients with difficult-to-treat genotype 1, researchers reported at the ... Hepatitis C meds GS-7977, daclatasvir and asunaprevir look good in interferon-free combos Liz Highleyman / 20 April 2012 Most previously untreated people with chronic hepatitis C achieved an early cure with an all-oral combination of the HCV NS5A inhibitor daclatasvir plus the polymerase inhibitor GS-7977, researchers reported on ... GS-7977 plus ribavirin rapidly suppresses HCV but most patients relapse Liz Highleyman / 07 March 2012 An interferon-free combination of the experimental polymerase inhibitor GS-7977 plus ribavirin potently and rapidly reduced hepatitis C virus (HCV) levels, but almost all patients experienced viral rebound after they stopped treatment, researchers reported ... ← Prev12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive